Canada Markets closed

Charles River Laboratories International, Inc. (CRL)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
225.02-11.19 (-4.74%)
At close: 04:00PM EDT
225.02 0.00 (0.00%)
After hours: 05:10PM EDT
Sign in to post a message.
  • B
    Bruce
    The question is will CLR work with NWBO now that Sawston, UK facility has been granted certification by the MHRA? In other words, Advent now has the capability to manufacture BIO vaccines using the Flaskworks device which is a highly automated vaccine manufacturing product (patent protected as of 3/8/22). Since the Sawston, UK facility can now replicate product it could transfer automated manufacturing process to CRL. There is a high probability that NWBO will continue to grow its DCVax-L production rate in the UK and CRL could help in other Countries as well. Also note the fact that compassionate care for cancer treatment is on the rise allowing a patient to bypass present SOC chemo. Just looking for feedback since CRL and NWBO would make a great team for CRL to manufacture the (DCVax-L, BIO) vaccines to help cure brain cancer and other cancers as well? As of 2022, there estimates that indicate at least 600,000 people are dying from brain cancer all over the world.
  • Y
    Yahoo Finance Insights
    Charles River Laboratories reached a 52 Week low at 228.21
  • Y
    Yahoo Finance Insights
    Charles River Laboratories reached a 52 Week low at 246.92
  • S
    Shelly
    Was a real fan favorite at one time.
    Over markets have some real drubbings.
    On my watch list for a later date.
  • K
    Keith
    Anyone aware of any news of substance that would account for the 6% decline today?
  • Y
    Yahoo Finance Insights
    Charles River Laboratories is down 5.78% to 238.70
  • B
    Bruce
    Will Charles River have any interest in Northwest Bio, NWBO since NWBO has interest in Cognate?
    The offer to purchase Cognate makes sense, and so does NWBO
  • Y
    Yahoo Finance Insights
    Charles River Laboratories is down 5.66% to 257.57
  • S
    S
    I can never find a good place to add to the shares I bought two years ago. This thing is a freight train! Finally broke down and bought 40 more at current levels. Not worked as I know this will break 1k in a year.
  • B
    Bruce
    Now that CRL has completed its acquisition of Cognate, will Charles River have any interest in Northwest Bio, NWBO since NWBO has interest in Cognate? It appears that NWBO is close to producing it first article vaccine in the UK and the USA within the next month or so? Many people are excited for both CRL and NWBO and they are expecting great news soon from NWBO.
  • Y
    Yahoo Finance Insights
    Charles River Laboratories is up 5.04% to 300.43
  • B
    Bruce
    Wed, May 12, 2021, 8:16 AM

    NWBO
    +4.29%
    Application Submitted to MHRA for Certification of Sawston Facility

    BETHESDA, Md., May 12, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that an application for certification of the manufacturing facility in Sawston, UK has been submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA). The Company also provided a process update on the DCVax®-L Phase III Trial.
    https://finance.yahoo.com/news/uk-manufacturing-facility-phase-iii-131600281.html
    Hope Cognate, now CRL follows the same path with ten fold the manufacturing capability for DCVax here in the US.
  • N
    Nogreenspanfan
    Anyone still holding the bag on this stock? Earnings announcement after the close today. The fact that it's getting pounded is a bad sign IMO. May be able to pick up shares on the cheap. Good company but way overvalued.
  • B
    Bruce
    Will Charles River have any interest in Northwest Bio, NWBO since NWBO has interest in Cognate?
    The offer to purchase Cognate makes sense, and so does NWBO
  • S
    S
    January 11, 2022--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced a retirement and transition plan for its Chief Financial Officer.

    David R. Smith, Corporate Executive Vice President and Chief Financial Officer, has announced that following a transition period, he will retire from Charles River after a distinguished career in healthcare and finance leadership roles. Mr. Smith will remain with the Company in his current position until a successor has been named and the transition has been completed, which is expected to occur before the end of 2022. Charles River is commencing a global search to identify its next Chief Financial Officer.
  • S
    Sander
    If I am right, its a EPS beat with $0.10
  • Y
    Yahoo Finance Insights
    Charles River Laboratories is down 5.39% to 276.26
  • B
    Bill Johnston
    The whole group is taking a beating. Can't find any news to account for it. Vaccine related?
  • B
    Bruce
    The question is will CLR work with NWBO now that Sawston, UK facility has been granted certification by the MHRA? In other words, Advent now has the capability to manufacture BIO vaccines using the Flaskworks device which is a highly automated vaccine manufacturing product. Since the Sawston, UK facility can now replicate product it could transfer automated manufacturing process to CRL. There is a high probability that NWBO will continue to grow its DCVax-L production rate in the UK and CRL could help in other Countries as well. Just looking for feedback since CRL and NWBO would make a great team for BIO vaccines to help cure brain cancer and other cancers as well?
  • S
    Stockguru
    Down $50 wow... Good buying opportunity but I'm waiting a few days to see if it goes lower.